Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus bevacizumab induction followed by chemoradiotherapy plus bevacizumab in locally advanced resectable rectal cancer
2011-003340-45Phase 2Active
- Sponsor
- Arco Therapeutics
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, irinotecan, oxaliplatin, fluorouracil, folinic acid and 1 more in rectal adenocarcinoma and rectal cancer, sponsored by Arco Therapeutics. Primary endpoint: Disease-free survival rate at 2 years. Started Mar 2012; status: active.
02
Drugs
bevacizumabirinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2011-003340-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003340-45.